Publicaciones en colaboración con investigadores/as de University of Western Australia (19)

2023

  1. Zanubrutinib Versus Ibrutinib in Symptomatic Waldenström Macroglobulinemia: Final Analysis From the Randomized Phase III ASPEN Study

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Vol. 41, Núm. 33, pp. 5099-5106

2022

  1. IBCL-117 ASPEN: Long-Term Follow-Up Results of a Phase 3 Randomized Trial of Zanubrutinib vs Ibrutinib in Patients With Waldenström Macroglobulinemia

    Clinical Lymphoma, Myeloma and Leukemia, Vol. 22, pp. S385

  2. Pooled safety analysis of zanubrutinib monotherapy in patients with B-cell malignancies

    Blood Advances

2020

  1. A randomized phase 3 trial of zanubrutinib vs ibrutinib in symptomatic Waldenström macroglobulinemia: The ASPEN study

    Blood, Vol. 136, Núm. 18, pp. 2038-2050

  2. Characteristics of Early Paget's Disease in SQSTM1 Mutation Carriers: Baseline Analysis of the ZiPP Study Cohort

    Journal of Bone and Mineral Research, Vol. 35, Núm. 7, pp. 1246-1252

  3. Zanubrutinib for the treatment of MYD88 wild-type Waldenström macroglobulinemia: A substudy of the phase 3 ASPEN trial

    Blood Advances, Vol. 4, Núm. 23, pp. 6009-6018

2019

  1. Zoledronate in the prevention of Paget's (ZiPP): Protocol for a randomised trial of genetic testing and targeted zoledronic acid therapy to prevent SQSTM1-mediated Paget's disease of bone

    BMJ Open, Vol. 9, Núm. 9

2018

  1. How immunological profile drives clinical phenotype of primary Sjögren's syndrome at diagnosis: Analysis of 10,500 patients (Sjögren Big Data Project)

    Clinical and Experimental Rheumatology, Vol. 36, pp. S102-S111

2017

  1. Predicting cardiovascular events in familial hypercholesterolemia: The SAFEHEART registry (Spanish Familial Hypercholesterolemia Cohort Study)

    Circulation, Vol. 135, Núm. 22, pp. 2133-2144

2016

  1. An international, multicenter, prospective, observational study of neutropenia in patients being treated with lenalidomide + dexamethasone for relapsed or relapsed/refractory multiple myeloma (RR-MM)

    American Journal of Hematology, Vol. 91, Núm. 8, pp. 806-811

  2. Attainment of LDL-cholesterol treatment goals in patients with familial hypercholesterolemia: 5-year SAFEHEART registry follow-up

    Journal of the American College of Cardiology, Vol. 67, Núm. 11, pp. 1278-1285

2014

  1. The IASLC/ITMIG thymic epithelial tumors staging project: Proposal for an evidence-based stage classification system for the forthcoming (8th) edition of the TNM classification of malignant tumors

    Journal of Thoracic Oncology, Vol. 9, Núm. 9, pp. S65-S72

  2. The IASLC/ITMIG thymic epithelial tumors staging project: Proposals for the N and M components for the forthcoming (8th) edition of the TNM classification of malignant tumors

    Journal of Thoracic Oncology, Vol. 9, Núm. 9, pp. S81-S87

  3. The IASLC/ITMIG thymic epithelial tumors staging project: Proposals for the T component for the forthcoming (8th) edition of the TNM classification of malignant tumors

    Journal of Thoracic Oncology, Vol. 9, Núm. 9, pp. S73-S80

2013

  1. Common susceptibility alleles and SQSTM1 mutations predict disease extent and severity in a multinational study of patients with Paget's disease

    Journal of Bone and Mineral Research, Vol. 28, Núm. 11, pp. 2338-2346

2011

  1. A single infusion of zoledronic acid produces sustained remissions in paget disease: Data to 6.5 years

    Journal of Bone and Mineral Research, Vol. 26, Núm. 9, pp. 2261-2270

2010

  1. A genome-wide association study for myopia and refractive error identifies a susceptibility locus at 15q25

    Nature Genetics, Vol. 42, Núm. 10, pp. 902-905

  2. International network of cancer genome projects

    Nature, Vol. 464, Núm. 7291, pp. 993-998

  3. Quality, quantity and harmony: The DataSHaPER approach to integrating data across bioclinical studies

    International Journal of Epidemiology, Vol. 39, Núm. 5, pp. 1383-1393